Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects.
Lipoprotein abnormalities [mainly high levels of very-low-density lipoprotein triglycerides (TG) and low levels of high-density lipoprotein cholesterol] increase the risk of cardiovascular disease in Type 2 diabetic patients. Moreover, only fasting TG and central obesity appear to independently predict mortality from CAD in glucose-intolerant and diabetic subjects. It is noteworthy that fasting lipid levels in these patients are often relatively unaffected, and that plasma TG may remain < 2 g/l, the cutoff point currently considered to define moderate hypertriglyceridemia. Our study of postprandial lipaemia shows that lipid intolerance (a greater increase of postprandial TG and a slower return towards basal levels) was almost always present in these patients, enabling us to detect atherogenic changes in plasma lipoproteins. Preliminary results indicate that fenofibrate treatment in Type 2 diabetes under optimised metabolic control improves not only fasting lipid levels but also postprandial lipaemia and associated abnormalities in lipoprotein levels and composition.
Cavallero
E
E
Service de Médecine Interne, Nutrition et Métabolisme de Lipides, Hôpital Henri Mondor, Créteil, France.
Piolot
A
A
Jacotot
B
B
D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004435:Eating / Q000502:physiology*; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D008074:Lipoproteins / Q000493:pharmacokinetics*; D008657:Metabolic Clearance Rate
D008074:Lipoproteins; D011345:Fenofibrate